Furthermore, the TATTON study (NCT02143466) has reported recently that combination of osimertinib and savolitinib (AZD6094) showed acceptable risk-benefit profile and encouraging anti-tumor activity in patients with EGFR mutation-positive, MET-amplified, advanced NSCLC, who had disease progression on a previous EGFR TKIs (73). This evidence concerns the gene EGFR and non-small cell lung carcinoma.